Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Lymphoma, B-Cell × tafasitamab × Clear all

Phase

Phase 2 2 Phase EARLY_PHASE1 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, B-Cell 1

Interventions

Rituximab 2 venetoclax 1 tafasitamab 1 pembrolizumab 1 glofitamab 1 fludarabine 1 avelumab 1 Valproic Acid 1 Melphalan 1 Ifosfamide 1 Gemcitabine 1 Etoposide 1 Dexamethasone 1 Cyclophosphamide 1 Cisplatin 1 Carboplatin 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04161248 2026-02-02

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Canadian Cancer Trials Group

Phase EARLY_PHASE1 Recruiting

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡